Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rapid Dose TherapeuticsRDTCF Days Payable is 744.44 as of May. 2026, which is 52% below its 10-year median of 1,557.84. The stock has 4 warning signs investors should review. Among 704 Biotechnology companies, Rapid Dose Therapeutics ranks better than 81.11% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RDTCF vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Rapid Dose Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rapid Dose Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rapid Dose Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Rapid Dose Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Rapid Dose Therapeutics's Days Payable for the fiscal year that ended in Feb. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rapid Dose Therapeutics (RDTCF) has a Days Payable of 744.44 as of May. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Rapid Dose Therapeutics and its competitors. This is 52% below median its historical median of 1,557.84. Over the past decade, Rapid Dose Therapeutics' Days Payable has ranged from 529.12 to 11,232.05. According to the industry distribution chart, Rapid Dose Therapeutics ranks #133 out of 704 companies in the Biotechnology industry, placing it in the top 18.9%.
Is Rapid Dose Therapeutics' Days Payable too high?
Rapid Dose Therapeutics' current Days Payable of 744.44 is 52% below median its 10-year median of 1,557.84. Over the past 10 years, this metric has ranged from a low of 529.12 to a high of 11,232.05. The Biotechnology industry median Days Payable is 110.01. Rapid Dose Therapeutics' value of 744.44 is 576.7% above this industry median. Based on the distribution chart, Rapid Dose Therapeutics ranks #133 out of 704 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Rapid Dose Therapeutics' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Rapid Dose Therapeutics ranks #133 out of 704 companies for Days Payable. This places Rapid Dose Therapeutics in the top 19% of its industry — outperforming the majority of peers. The industry median Days Payable is 110.01. Rapid Dose Therapeutics' value of 744.44 is 576.7% above this benchmark. Historically, Rapid Dose Therapeutics' own Days Payable has ranged from 529.12 to 11,232.05 over the past decade. While the company's 10-year median is 1,557.84 vs. the industry median of 110.01, Rapid Dose Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 110.01, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rapid Dose Therapeutics's current Days Payable of 744.44 is 576.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Rapid Dose Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 110.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rapid Dose Therapeutics's current Days Payable is 744.44, which is 52% below median its own 10-year median of 1,557.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapid Dose Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Rapid Dose Therapeutics (RDTCF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.20, compared to a current price of $0.09 — trading 57.5% below its estimated fair value. The current Days Payable is 744.44, which is 52% below median its 10-year median of 1,557.84 and 576.7% above the Biotechnology industry median of 110.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Rapid Dose Therapeutics (RDTCF), the current Days Payable is 744.44 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rapid Dose Therapeutics Corp is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, and cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RDTCF has been successfully added to your 
